Skip to main content
. Author manuscript; available in PMC: 2024 Feb 8.
Published in final edited form as: NEJM Evid. 2023 Dec 26;3(1):EVIDoa2300171. doi: 10.1056/EVIDoa2300171

Figure 2. Change in Prostate-Specific Antigen (PSA) after Treatment with ODM-208.

Figure 2.

Best change (percentage) in PSA from baseline in the total phase 1 population (Panel A) and in the androgen receptor gene mutation (ARmut) subpopulation (inset) and in phase 2 (Panel B). Change in PSA from baseline over time in individual patients in phase 1 (Panel C) and phase 2 (Panel D) by androgen receptor gene mutation status. ARwt denotes androgen receptor gene wild type; and mo, months.